Skip to content Skip to footer

BioArctic and Lilly Sign Research and Collaboration Agreement ~$800M to Advance Neurodegenerative Disease Therapy

Shots: BioArctic entered a research and collaboration agreement with Eli Lilly and Company to develop a potential treatment for neurodegenerative diseases by combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate Under the agreement, BioArctic will generate a new drug candidate incorporating its BrainTransporter platform, while Lilly will assume full responsibility for the…

Read more

BioArctic and Novartis sign agreement for BrainTransporter ~$802M

Shots: BioArctic has entered into an option, collaboration, and license agreement with Novartis to develop a neurodegeneration treatment using BrainTransporter As per the deal, BioArctic receives $30M upfront and could earn up to $772M in milestones plus tiered mid-single-digit royalties if Novartis licenses and commercializes the drug BioArctic will develop a drug candidate using BrainTransporter and a Novartis…

Read more